{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:58:20Z","timestamp":1791644300334,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>There is insufficient evidence regarding the efficacy and safety of stem cell therapy for autism spectrum disorders. We performed the first meta-analysis of stem cell therapy for autism spectrum disorders in children to provide evidence for clinical rehabilitation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The data source includes PubMed\/Medline, Web of Science, EMBASE, Cochrane Library and China Academic Journal, from inception to 24th JULY 2021. After sifting through the literature, the Cochrane tool was applied to assess the risk of bias. Finally, we extracted data from these studies and calculated pooled efficacy and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>5 studies that met the inclusion criteria were included in current analysis. Meta-analysis was performed using rehabilitation therapy as the reference standard. Data showed that the Childhood Autism Rating Scale score of stem cell group was striking lower than the control group (WMD: \u22125.96; 95%CI [\u22128.87, \u22123.06]; <jats:italic>p<\/jats:italic> &amp;lt; 0.0001). The Clinical Global Impression score consolidated effect size RR = 1.01, 95%CI [0.87, 1.18], Z = 0.14 (<jats:italic>p<\/jats:italic> = 0.89), the effective rate for The Clinical Global Impression was 62% and 60% in the stem cell group and the control group, respectively. The occurrence events of adverse reactions in each group (RR = 1.55; 95%CI = 0.60 to 3.98; <jats:italic>p<\/jats:italic> = 0.36), there was no significant difference in the incidence of adverse reactions between the stem cell group and the control group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results of this meta-analysis suggested that stem cell therapy for children with autism might be safe and effective. However, the evidence was compromised by the limitations in current study size, lacking standardized injection routes and doses of stem cells, as well as shortages in diagnostic tools and long period follow-up studies. Hence, it calls for more studies to systematically confirm the efficacy and safety of stem cell therapy for children with autism spectrum disorders.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.897398","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T07:26:53Z","timestamp":1651649213000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and Safety of Stem Cell Therapy in Children With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Jiayang","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lincai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaolin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e20193447","DOI":"10.1542\/9781610024716-part01-ch002","article-title":"Identification, evaluation, and management of children with autism spectrum disorder","volume":"145","author":"Hyman","year":"2020","journal-title":"Pediatrics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1038\/s41467-021-23987-z","article-title":"FoxG1 regulates the formation of cortical GABAergic circuit during an early postnatal critical period resulting in autism spectrum disorder-like phenotypes","volume":"12","author":"Miyoshi","year":"2021","journal-title":"Nat Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.7150\/ijbs.24063","article-title":"The prevalence of autism spectrum disorders in China: a comprehensive meta-analysis","volume":"14","author":"Wang","year":"2018","journal-title":"Int J Biol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"112679","DOI":"10.1016\/j.psychres.2019.112679","article-title":"Prevalence of autism spectrum disorder in Asia: a systematic review and meta-analysis","volume":"284","author":"Qiu","year":"2020","journal-title":"Psychiatry Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/jpm11090848","article-title":"Molecular dysregulation in autism spectrum disorder","volume":"11","author":"Gill","year":"2021","journal-title":"J Pers Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/npp.2016.158","article-title":"The role of the immune system in autism spectrum disorder","volume":"42","author":"Meltzer","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fnhum.2013.00733","article-title":"Heterogeneity within autism spectrum disorders: what have we learned from neuroimaging studies?","volume":"7","author":"Lenroot","year":"2013","journal-title":"Front Hum Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"625978","DOI":"10.3389\/fpsyt.2021.625978","article-title":"Automatic classification of adult males with and without autism spectrum disorder by non-contact measurement of autonomic nervous system activation","volume":"12","author":"Doi","year":"2021","journal-title":"Front Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12967-015-0642-6","article-title":"LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b","volume":"13","author":"Ti","year":"2015","journal-title":"J Transl Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3727\/096368910X508762","article-title":"Mesenchymal stem cells: mechanisms of immunomodulation and homing","volume":"19","author":"Yagi","year":"2010","journal-title":"Cell Transplant."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/sj.leu.2402256","article-title":"Homing, cell cycle kinetics and fate of transplanted hematopoietic stem cells","volume":"15","author":"Srour","year":"2001","journal-title":"Leukemia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1634\/stemcells.2007-0197","article-title":"Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing","volume":"25","author":"Chamberlain","year":"2007","journal-title":"Stem Cells (Dayton, Ohio)."},{"key":"B13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cyto.a.23242","article-title":"Isolation, cultivation, and characterization of human mesenchymal stem cells","volume":"93","author":"Mushahary","year":"2018","journal-title":"Cytometry A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00441-016-2462-2","article-title":"MicroRNAs in regulation of osteogenic differentiation of mesenchymal stem cells","volume":"368","author":"Huang","year":"2017","journal-title":"Cell Tissue Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e12445","DOI":"10.1111\/appy.12445","article-title":"Intrathecal autologous bone marrow stem cell therapy in children with autism: a randomized controlled trial","volume":"13","author":"Sharifzadeh","year":"2021","journal-title":"Asia Pac Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/sctm.20-0102","article-title":"Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder","volume":"10","author":"Nguyen Thanh","year":"2021","journal-title":"Stem Cells Transl Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"623875","DOI":"10.1155\/2013\/623875","article-title":"Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study","volume":"2013","author":"Sharma","year":"2013","journal-title":"Stem Cells Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.3727\/096368914X684916","article-title":"Efficacy of fetal stem cell transplantation in autism spectrum disorders: an open-labeled pilot study","volume":"1","author":"Bradstreet","year":"2014","journal-title":"Cell Transplant."},{"key":"B19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/1479-5876-11-196","article-title":"Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism","volume":"11","author":"Lv","year":"2013","journal-title":"J Transl Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/sctm.19-0010","article-title":"Allogeneic human umbilical cord mesenchymal stem cells for the treatment of autism spectrum disorder in children: safety profile and effect on cytokine levels","volume":"8","author":"Riordan","year":"2019","journal-title":"Stem Cells Transl Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"Ed000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B22","article-title":"Intrathecal autologous bone marrow stem cell therapy in children with autism: a randomized controlled trial","author":"Sharifzadeh","year":"2020","journal-title":"Asia-pacific psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.3969\/j.issn.1673-8225.2011.23.041","article-title":"Safety and efficacy of cord blood mononuclear cells and umbilical cord mesenchymal stem cells therapy for childhood autism","volume":"15","author":"Liu","year":"2011","journal-title":"J Clin Rehabil Tissue Eng Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpeds.2020.03.011","article-title":"A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder","volume":"222","author":"Dawson","year":"2020","journal-title":"J Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/sctm.17-0042","article-title":"Safety and Observations from a placebo-controlled, crossover study to assess use of autologous umbilical cord blood stem cells to improve symptoms in children with autism","volume":"7","author":"Chez","year":"2018","journal-title":"Stem Cells Transl Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12015-021-10257-0","article-title":"Stem cell therapy in the treatment of patients with autism spectrum disorder: a systematic review and meta-analysis","volume":"18","author":"Villarreal-Mart\u00ednez","year":"2022","journal-title":"Stem Cell Rev Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/sctm.16-0474","article-title":"Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial","volume":"6","author":"Dawson","year":"2017","journal-title":"Stem Cells Transl Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.biotechadv.2018.03.011","article-title":"Stem cells: their source, potency and use in regenerative therapies with focus on adipose-derived stem cells - a review","volume":"36","author":"Bacakova","year":"2018","journal-title":"Biotechnol Adv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"8922","DOI":"10.1073\/pnas.1505464112","article-title":"Stem cells are units of natural selection for tissue formation, for germline development, and in cancer development","volume":"112","author":"Weissman","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMra1804280","article-title":"Clinical and therapeutic implications of cancer stem cells","volume":"380","author":"Clarke","year":"2019","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"630932","DOI":"10.1155\/2015\/630932","article-title":"Clinical trial of human fetal brain-derived neural stem\/progenitor cell transplantation in patients with traumatic cervical spinal cord injury","volume":"2015","author":"Shin","year":"2015","journal-title":"Neural Plast."},{"key":"B32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/neuros\/nyx250","article-title":"Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury","volume":"82","author":"Levi","year":"2018","journal-title":"Neurosurgery."},{"key":"B33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/neu.2018.5843","article-title":"Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury","volume":"36","author":"Levi","year":"2019","journal-title":"J Neurotrauma."},{"key":"B34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.stem.2018.05.014","article-title":"A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury","volume":"22","author":"Curtis","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet (London, England)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41591-020-1050-x","article-title":"Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study","volume":"26","author":"Bloor","year":"2020","journal-title":"Nat Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2337\/db18-0699","article-title":"Potential of allogeneic adipose-derived stem cell-hydrogel complex for treating diabetic foot ulcers","volume":"68","author":"Moon","year":"2019","journal-title":"Diabetes."},{"key":"B38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2337\/db14-0656","article-title":"Preserved \u03b2-cell function in type 1 diabetes by mesenchymal stromal cells","volume":"64","author":"Carlsson","year":"2015","journal-title":"Diabetes."},{"key":"B39","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3389\/fimmu.2020.00993","article-title":"Allogenic adipose tissue-derived stromal\/stem cells and vitamin D supplementation in patients with recent-onset type 1 diabetes mellitus: a 3-Month follow-up pilot study","volume":"11","author":"Araujo","year":"2020","journal-title":"Front Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S1474-4422(17)30046-7","article-title":"Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"16","author":"Hess","year":"2017","journal-title":"The Lancet Neurology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/jnnp-2019-322515","article-title":"Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2)","volume":"91","author":"Muir","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/brainsci11030340","article-title":"Estimating components and costs of standard care for children with autism spectrum disorder in Europe from a large international sample","volume":"11","author":"Bieleninik","year":"2021","journal-title":"Brain Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1200\/OP.20.00170","article-title":"Length of stay and hospital costs for patients undergoing allogeneic stem-cell transplantation","volume":"17","author":"Godara","year":"2021","journal-title":"JCO oncology practice."},{"key":"B44","first-page":"5967","article-title":"Stem cells for treatment of autism: safety and efficacy","volume":"14","author":"Min","year":"2010","journal-title":"J Clin Rehabilitative Tissue Engineering Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jnr.24548","article-title":"Umbilical cord blood stem cell therapy in premature brain injury: opportunities and challenges","volume":"98","author":"Peng","year":"2020","journal-title":"J Neurosci Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jpeds.2020.11.063","article-title":"A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder","volume":"230","author":"Nguyen","year":"2021","journal-title":"J Pediatr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mpr.1466","article-title":"Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems","volume":"24","author":"Brugha","year":"2015","journal-title":"Int J Methods Psychiatr Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fncel.2020.00059","article-title":"Cell type-specific gene network-based analysis depicts the heterogeneity of autism spectrum disorder","volume":"14","author":"Guan","year":"2020","journal-title":"Front Cell Neurosci."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.897398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T07:27:12Z","timestamp":1651649232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.897398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":48,"alternative-id":["10.3389\/fped.2022.897398"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.897398","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"article-number":"897398"}}